11.76 USD
▲-0.17+4.26%
盘后 11.30 +0.18%
2026-08-03
市值
$1.03B
市盈率
—
EPS
-2.03
股息率
—
52 周区间
4.47 – 36.26
成交量
1.16M
Beta
2.01
目标价
40.70
52W 低 4.4752W 高 36.26
价格走势
公司简介
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. The company’s lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in seco...